YCCI Staff Updates

Helen Seow

Helen Seow, Ph.D., Associate Director of Research Administration, YCCI

New Associate Director of Research Administration Brings Scientific Expertise to YCCI

YCCI welcomes research scientist Helen Seow, Ph.D., as associate director of research administration as of September 10, 2012. Seow, who has been a member of Yale’s research faculty since 2006, brings expertise in oncology, pharmacology, drug discovery, and preclinical investigation to her new role. In her previous position, she led and managed several research projects to evaluate new anticancer agents. Under her leadership, the compound KS119 was identified as a potential anticancer agent for the treatment of solid tumors. She also supported research efforts to determine the mechanism of action of the anticancer drug laromustine, which was evaluated in a phase III clinical trial for use in patients with acute myelogenous leukemia. Seow has collaborated on the design and development of novel cell-based assays for targeting clinically identified drug-resistant phenotypes. She is also associate editor of Oncology Research

In her new position, Seow will oversee YCCI’s scientific operational and research administration, evaluating current programs to determine how they can be improved from the scientific perspective. She will be also be involved in developing and implementing programs that link clinical and translational research with basic science research, and will oversee the biospecimen repository that is being developed in conjunction with OnCore. “I’m looking forward to becoming more involved in the clinical world and moving discoveries from the bench to the bedside,” she said.

Kelly Anastasio

Kelly Anastasio, Associate Director of Clinical Trials, YCCI

New Associate Director of Clinical Trial Resources Will Provide Additional Support for Researchers

As part of a reorganization of YCCI’s administrative structure to better meet the demands of Yale’s clinical and translational research enterprise, Kelly Anastasio joined the center as associate director of clinical trial resources in September. 

Anastasio has spent the last six years as clinical research and reimbursement manager in the department of orthopaedics, where she was responsible for managing clinical trial activity including budget development, contract negotiations, clinical trials matrix, and operational flow. Her outstanding contributions have had a positive impact on the department’s performance, contributing to record levels of accomplishment and she was awarded the Leadership in Research Billing Compliance Award by Yale Medial Group Compliance in 2009. Anastasio is a certified Professional Medical Coding Curriculum instructor whose previous experience includes teaching for the Medical Coding Academy in Branford, CT for the past six years and at The Coding Center of Connecticut prior to that. Her organizational and managerial skills will be an asset to YCCI as it seeks to broaden its ability to provide these critical services to investigators across the health campus. 

YCCI offers a wide array of services and resources to support all aspects of clinical and translational research. YCCI staff members help Yale investigators navigate the complex research landscape, lessening administrative burdens and ensuring that studies are conducted safely and efficiently. In her new role, Anastasio will help to pinpoint resources for investigators and develop tools that allow them to transform research ideas into completed studies. She will apply her expertise not only to getting studies up and running, but to sustaining them as well. She will also play a major role in the implementation of OnCore, Yale’s clinical trials management system, helping to ensure a smooth and compliant transition across departments in the School of Medicine and YNHH. 

“Kelly’s broad knowledge and skillful experience in managing all aspects of clinical trials will be a critical asset to YCCI and Yale Medical School overall,” said Steven Gentile, associate chair of finance and administration for cardiovascular medicine in the Department of Internal Medicine. “Her drive and passion for clinical research is unmatched; and I expect she will be instrumental in helping the Center reach a new level of expertise and achievement.”

New Training Initiative for Research Staff and Faculty

YCCI is pleased to announce that our popular monthly Lunch and Learn sessions will expand to include a monthly Coffee and Conversation series. These series will address a broad range of topics related to clinical trials management and are open to all clinical research faculty and staff. 

To view the schedule click here. For more information, contact LaToya Howard at latoya.howard@yale.edu or call 737-3661.

Biospecimen Management Coming Soon

OnCore’s biospecimen management capability will soon begin to roll out, with the Yale Cancer Center Core lab the first to implement the new platform. 

The new module will be integrated with the clinical trial management system, enabling the tracking of fully bar-coded specimens and allowing for data capture of collection, processing, storage, and shipment information. The module also connects the regulatory aspects of sample management with the actual specimens, enabling investigators to ascertain how the samples may be used. 

The new functionality is expected to facilitate the launch of a sample repository of healthy volunteers and to help manage large animal specimens. Its flexibility means it can be used not only for large multicenter studies but also for smaller individual studies. Its capabilities include: 

  • Inventory management 
  • Requisition and distribution management
  • Correlative study sample management 
  • Flexible reporting capabilities 
Enterprise-wide implementation is expected to take over a year because each of Yale’s labs has its own samples and data that must be imported into the new system. “We’ve been wanting to have biospecimen management capability for some time, but it made sense to integrate it with our clinical trials management system and the process required careful planning,” said Kevan Herold, M.D., YCCI’s deputy director for translational science. “It will be an enormous resource for investigators.”